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       INTRODUCTION 
 
 
Endotracheal intubation is an integral part of administration of 
anaesthesia during surgical procedure. 
 
Succinylcholine, a depolarizing muscle relaxant with rapid onset of 
action and short duration is still the relaxant of choice to facilitate tracheal 
intubation. But in addition to fasciculations, succinylcholine has many side 
effects such as bradycardia, dysrhythmias, increased release of potassium, 
postop myalgia, increased intra ocular pressure, intra cranial tension, intra 
gastric pressure, prolonged recovery in patients with pseudocholinesterase 
deficiency, masseter spasm and triggering malignant hyperthermia1,2,3,4,6,7. 
 
Since these side effects are due to depolarizing mechanism of action 
of Succinylcholine, search has been focused on to find an ideal non 
depolarizing muscle relaxant with rapid onset time and offering excellent 
intubating conditions and also lacking all the above mentioned side effects5.  
 
Pancuronium: 
Pancuronium is a bisquaternary aminosteroid nondepolarizing 
neuromuscular-blocking drug with an ED95 of 70 µg/kg that has an onset of 
action in 3 to 5 minutes and a duration of neuromuscular blockade lasting 
60 to 90 minutes. Respiratory acidosis enhances pancuronium–induced 
neuromuscular blockade and opposes its antagonism with neostigmine8. 
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Doxacurium:  
Doxacurium is a benzylisoquinolinium nondepolarizing          
neuromuscular blocking drug with an ED95 of 30 µg/kg that has an onset of 
action in 4 to 6 minutes and a duration of neuromuscular blockade lasting 
60 to 90 minutes. The pharmacokinetics of doxacurium resemble 
pancuronium with respect to dependence on renal clearance9,10. 
 
Atracurium:  
Atracurium is a bisquaternary benzylisoquinolinium non-
depolarizing neuromuscular-blocking drug with an ED95 of 0.2 mg/kg that 
has an onset of action in 3 to 5 minutes and a duration of neuromuscular 
blockade lasting 20 to 35 minutes. Large bolus dose of 1.5mg/kg will allow 
intubation in 90 sec but has hypotension, tachycardia and histamine release 
as side effects11. 
 
Cisatracurium:  
Cisatracurium is a benzylisoquinolinium nondepolarizing 
neuromuscular-blocking drug with an ED95 of 50 µg/kg that has onset of 
action in 3 to 5 minutes and duration of neuromuscular blockade lasting 20 
to 35 minutes.  
 
Vecuronium: 
Vecuronium is a monoquaternary aminosteroid nondepolarizing 
neuromuscular - blocking drug with an ED95 of 50µg/kg that has an onset 
of action in 3 to 5 minutes and a duration of neuromuscular blockade 
lasting 20 to 35 minutes. This drug provides greater hemodynamic 
stability12.  
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Rocuronium: 
Rocuronium is a monoquaternary aminosteroid nondepolarizing  
neuromuscular-blocking drug with an ED95 of 0.3mg /kg  with an onset of 
action in 1 to 2 minutes and a duration of neuromuscular blockade lasting 
20 to 35 minutes. It has rapid onset with insignificant cardiovascular effects 
and ultimate safety profile11,12.   
 
An ideal muscle relaxant must have following properties :- 
(i) Rapid onset of action  
(ii) Minimal cardiovascular side effects  
(iii) Less cumulative effects 
(iv) Less dependence  on  hepatic or renal function for its metabolism  
       and excretion  
(v) No histamine release  
(vi) Pharmacologically inactive metabolite.  
(vii) Easily antagonized      
 
Of all the available relaxants, ROCURONIUM and VECURONIUM 
retain the advantages while eliminating the disadvantages of other drugs. 
Among these two, rocuronium comes ahead because of its more rapid onset 
of action while retaining all the benefits of vecuronium. Hence these two 
drug were compared in this study.  
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AIM OF THE STUDY 
 
The aim of the present study is to find an ideal intubating dose of Inj. 
Rocuronium bromide  0.6mg/kg (2 ED 95) and 0.9mg/kg (3 ED 95) 
comparing with Inj. Vecuronium bromide 0.1mg /kg (2 ED 95) as control 
with regards to  
 
• Intubating conditions  
• Onset of blockade or time to maximum blockade  
• Duration of blockade 
• Hemodynamic stability  
 
 
 
11 
 
HISTORY 
 
1555   :  Tracheal insufflations in animals was described  by  
Andreas Vesalius  of Padua.  
 
1978   :  William Mc Even of Glasgow passed a tube from mouth  
into  trachea using finger as a guide in conscious patient. 
 
1907   :  Barthelemy and Dufour of Nancy, blew chloroform  
vapor and air   from a Vernon Harcount inhaler and a 
rubber guided into the  trachea by touch.  
 
1928  :  Magill published the results of blind nasal intubation  
with wide bore tube. The first blind nasal intubation was 
performed by Stanley Rowbotham. Use of muscle 
relaxant was pioneered by Bourne to facilitate 
intubation. 
 
1850  :    Claude Bernard showed  Curare acts by paralyzing myo- 
neural junction .This led to his discovery of  the concept 
of motor end plate. 
 
1934   : Sir Henry Dale described the   physiological  actions  
of Acetylcholine and its  association with    
neuromuscular transmission.   
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1935  : King isolated active compound from the  
   Chondrodendron species and called it D-tubocurarine. 
 
1938  : Richard Gill returned from Ecuador with 11 kg of dark  
   tarlike paste, crude curare mixture. 
 
1940  : Squibb and Sons, Inc., prepared Intocostrin from the  
   dark tarlike paste. 
  
1942  :  Harold R.Griffith and Enid Johnson used curare to give  
relaxation during surgery on 23rd January in Montreal, 
Canada.  
 
 
1949  :  Daniel Bovet et al introduced Suxamethonium. 
 
 
1951   :  Suxamethonium was first used in anaesthesia by Otto  
Van Dardel in Stockholm and Otto Meyerhofer in 
Vienna.  
 
 
 
1956  : W.D.M. Paton made the distinction between  
depolarizing and  nondepolarizing  muscle  relaxants.  
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ANATOMY AND PHYSIOLOGY 
 
Neuro Muscular Junction : 
 Neuro Muscular Junction is  specialized on the nerve side and on the 
muscle side to transmit and receive chemical  messages . Each motor 
neuron runs without interruption from ventral horn of the spinal cord to 
Neuro Muscular Junction as large myelinated axon. As it approaches the 
muscle, it repeatedly branches to contact many muscle cells.  
 
Motor end plate: 
The nerve axon with all the muscle fibers it innervates form the 
motor end plate.  
 
The parts of Neuro Muscular Junction are, 
 
 
Presynaptic Nerve terminal : 
The architecture of nerve   terminal is different from that of axon. As 
the nerve terminal reaches  the muscle  fibers, it loses its myelin to form a 
splay of terminal branches against the muscle surface. This is covered by 
Schwann cells. This is the synaptic area of muscle membrane. The vesicles 
containing acetylcholine are ordered in repeating clusters along active 
zones or release sites. The active zones are areas where vesicles attach and 
rupture.  
 
 
Synaptic cleft:  
The nerve is separated from the surface of the muscle by a gap of 
50nm, called the junctional cleft. The nerve and muscle are held tightly by 
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protein  filaments called basal lamina, which spans the cleft between nerve 
and end plate13.  
 
Post synaptic muscle membrane:  
The muscle surface is heavily corrugated with  deep invaginations of 
the junctional  cleft. They are the primary and secondary clefts between 
folds in the muscle membrane forming troughs  and shoulders. This makes  
the end plate’s total surface area very large. The shoulders of the fold are 
densely populated with acetylcholine  receptors, about 5 million in each 
junction. The troughs have secondary clefts which contain sodium 
channels14.  
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Contractile apparatus : 
 
The contractile apparatus of the muscle is formed by the 
myofilament comprising of the thin actin filaments and thick myosin 
filaments along with tropomyosin, troponin I, T and C. Tropomyosin is 
attached to the myosin binding site of action.  
 
  The myofilaments combine to form myofibrils. The muscle plasma 
membrane, the sarcolemma, invaginates to form T-tubules which lie in 
close association with sarcoplasmic reticulum, which is a collection of sacs 
and tubules acting as a reservoir for calcium.   
 
Perijunctional zone: 
Area of muscle immediately beyond the junctional area is the 
perijunctional zone, and it is critical to the function of neuro muscular 
junction. This zone contains  mixture of receptors, which include a small 
number of acetylcholine receptors and a large number of  sodium channels. 
This mixture increases the response to depolarization produced by 
acetylcholine receptors and transduces it into wave of depolarization that 
travels along muscle to initiate muscle contraction.  
 
Mechanism of Acetylcholine Release : 
Quantal theory  : 
While observing the electrophysiologic activity of skeletal muscles, 
small spontaneous, depolarizing potentials at neuro muscular junction are 
seen. These potentials have only one hundredth the amplitude of the evoked 
end potential when the motor nerve is stimulated. These small amplitude 
potentials are called miniature end plate potential (MEPPs). MEPPs are 
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unitary responses and sizes of all MEPPs are equal to or multiples of the 
minimum size. MEPPs are produced in uniform sized packages called 
quanta. The stimulus evoked motor potential is the additive depolarization 
produced by synchronous discharge of quanta from several hundred 
vesicles14,15.  
 
Formation of Acetylcholine at nerve endings : 
Choline, transported by a special  system from the extra cellular fluid 
to the  cytoplasm and acetate in the form of acetyl Co enzyme A combine 
in presence of acetyl transferase to form acetylcholine. 
  
ECF        → 
 
 
 AcetylCoEA→ 
Choline 
+ 
Acetate 
Acetyl 
→ 
transferase 
Acetyl  
 
Choline  
  
 The acetylcholine is stored in cytoplasm and transported as vesicles 
during release14,15. 
 
Binding of acetylcholine to receptor 
 The acetylcholine  released from nerve diffuses across the junctional 
cleft and reacts with specialized receptor proteins in the end plate to initiate 
muscle contraction. Two isoforms of post junctional receptors exist, a 
junctional or mature and extrajunctional or immature receptor.  
 
 Acetylcholine receptors  are synthesized in muscle cell and anchored 
to end plate membrane by 43 kd protein rapsyn in 1:1 ratio. These receptors 
have 5 subunits. The proteins are arranged like staves of a barrel with a 
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central pore for ion channeling. The receptor protein has a mass of 2,50,000 
daltons. The 5 subunits are 2α, β,δ, ε or γ. Each subunit consists of 400-500 
amino acids. The mass of each subunit is α :40000, β: 50000, δ:65000, 
ε:55000 and γ:60000 daltons16. The receptor protein complex passes 
through the membrane and protrudes beyond the surface of membrane into 
cytoplasm. The extrajunctional receptors have γ instead of δ as subunits. 
The acetylcholine binds to each of α subunits17.  
 
 
 
 
 
 
 
Immature Acetylcholine  Receptor              Mature Acetylcholine  Receptor  
 
 
 
 
 
 
Neuronal Acetylcholine  Receptor 
 
 
Acetylcholinesterase  
 Acetylcholine released from nerve diffuses across junctional cleft 
and reacts with specialized receptor protein to initiate muscle contraction. 
Transmitter molecules that do not react immediately with a receptor or 
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those relapsed after binding to the receptor are destroyed instantaneously by 
acetylcholinesterase in the junctional cleft14,15,17. Acetylcholinesterase is  a 
type B carboxylesterase enzyme. Acetylcholine is a potent messenger but 
its actions are very short lived because it is destroyed in less than 1ms after 
release.  
 
Extrajunctional nAChRs: 
 Normally these receptors are not present in large numbers since their 
synthesis is suppressed by neural activity. During conditions like trauma, 
skeletal denervation or burns these extrajunctional receptors proliferate 
rapidly. These receptors appear over the entire post junctional membrane 
rather than being confined to the area of neuromuscular junction18. 
 
Perijunctional nAChRs: 
 These receptors in motor nerve endings influence the release of 
neurotransmission. These prejunctional nAChRs are different from 
postjunctional nAChRs in their chemical binding characteristics, the nature 
of the ion channel they control and their preferential blockade during high 
frequency stimulation18.   
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Basic Electrophysiology of Neurotransmission  
 The electrophysiology is studied by patch clamp test. The ion 
channel is inactive and does not open in absence of acetylcholine. Even 
binding of one α sub unit to acetylcholine does not open. Both α subunit 
must be occupied to cause conformational change to open the channel and 
allow sodium and calcium ions inside and potassium outside. When the one 
of two sites is occupied by antagonist like curare, the receptor will not open 
even if the other binding site is occupied by acetylcholine. The current 
carried by the ions depolarizes the adjacent membrane. The net 
depolarizing current causes the muscles to contract. The pulse stops when 
the channel closes and one or both agonist molecules detach from the 
receptor. Each burst of acetylcholine from the nerve normally opens about 
5,00,000 channels causing depolarization and contraction17,18. 
 
MECHANISM OF DEPOLARIZING BLOCKADE 
 
 Depolarizing relaxants, simulate the effects of acetylcholine and 
hence considered as agonists. Succinylcholine is two molecules of 
acetylcholine attached together. Succinylcholine or decamethonium can 
bind to one or both of α receptor, open the channel, pass current and 
depolarize the end plate. Depolarizing relaxants have biphasic action:  an 
initial contraction followed by relaxation lasting from minutes to hours. 
Their action lasts till the depolarizing agents are cleared by plasma since 
they are not subject to hydrolysis by acetylcholinesterase. 
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Features of depolarizing blockade: 
1. Decreased contraction in response to single twitch stimulation 
2. Decreased amplitude but sustained response to continuous 
stimulation.  
3. TOF ratio >0.7 
4. Absence of post tetanic facilitation  
5. Augmentation of neuro muscular blockade after administration of 
anticholinesterase drug  
6. Onset of phase I blockade is accompanied by skeletal muscle 
fasciculation.   
Sodium channels: 
     
 
 
 
 
 
 
 The quick shift from excitation of muscle  contraction to blockade of 
transmission by  depolarizing agents occurs because the end plate is 
continuously depolarized. This occurs because of ion channel, the sodium 
channel which does not respond to chemicals but opens when exposed to a 
transmembrane voltage change. 
 
 Sodium channel has two gates. In the resting state, the lower gate 
(time dependent or inactivation gate) is open but the upper gate (voltage 
dependant gate) is closed and sodium cannot pass. 
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 During depolarization the top gate opens and because lower gate is 
also open, sodium flows through the channel. This stays open as long as the 
molecule is subject to depolarization. But shortly after this the voltage 
dependant gate remains open but the bottom gate is closed. This cuts off ion 
flow and time dependant gate does not open until voltage dependent gate 
closes. When depolarization stops, the voltage dependant gate closes, time 
dependant gate opens and sodium channel comes to a resting state19. 
 
Phase I block  
 The succinylcholine molecule is  attached to one or both α subunit of 
acetylcholine receptor, depolarizing the postjunctional membrane. But 
since hydrolysis of succinylcholine is slow there is sustained depolarization  
called phase I blockade.  
 
Phase II block  
 A complex  phenomenon which occurs on continuous exposure to 
depolarizing agent or when large dose of succinylcholine (>2mg / kg IV) is 
given as infusion. The postjunctional membrane does not respond to 
acetylcholine  even after depolarization. Resembles block produced by non 
depolarizing muscle relaxants. But reversal with cholinesterase inhibitors is 
not attempted. 
 
 In depolarizing block, muscle membrane is divided into 3 zones. 
• End plate : Depolarized by succinylcholine  
• Post junctional membrane: Sodium channels are frozen in an 
activated state.  
• Rest of muscle membrane : Sodium channels are in resting excitable 
state.  
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 This phenomenon is called as accommodation where synapse is 
unexcitable through the nerve (transmitter) but direct electrical stimulation 
of muscle will cause muscle contraction since sodium channels beyond the 
junctional area are in resting state. Accommodation does not occur in extra 
ocular muscle.  
 
MECHANISM OF NON DEPOLARIZING BLOCKADE: 
 
 These act by combining with nicotinic acetylcholine receptors 
without causing any activation of these ion  receptor channels. These drugs 
can act competitively with acetylcholine on α subunit of post junctional 
receptors without causing a change in the configuration of these receptor.  
 
Features of non depolarizing muscle relaxants: 
(i) Decreased twitch response to single stimulus 
(ii) Unsustained response (fade) during continuous stimulation  
(iii) TOF ratio <0.7  
(iv) Post tetanic potentiation  
(v) Potentiation of other non depolarizing muscle relaxants  
(vi) Antagonism by anticholinesterase drugs   
(vii) No skeletal muscle fasciculation seen.   
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            NEUROMUSCULAR MONITORING 
 
 Neuromuscular function is monitored by evaluating the muscular  
response to supra maximal stimulation of a peripheral motor nerve.  
 
Types of Neuromuscular stimulation: 
1. Electrical  : Most commonly used  
2. Magnetic:  Less painful and does not need contact with the body. But   
equipment is very heavy, cannot be used for TOF stimulation and 
difficult to achieve supra maximal stimulation. Hence seldom used.  
 
Principles of peripheral nerve stimulation  
 The reaction of a single muscle fiber to a stimulus follows an all or 
none pattern. If the nerve is stimulated with sufficient intensity, all muscle 
fibers supplied by that nerve will react and maximum response is obtained. 
The reduction in response during constant stimulus reflects neuromuscular 
blockade. 
 
 The stimulus is 20-25% above that needed for maximal response. 
Hence called as supramaximal.     
 
Patterns of Neuromuscular stimulation 
 The most commonly used patterns of electrical nerve stimulation are 
single twitch, Train of four , tetanic count,  post tetanic count and double 
burst stimulation13,18. 
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Single twitch stimulation: 
 Here  single supramaximal electrical stimuli is applied to a peripheral 
motor nerve at frequencies from 1.0Hz (once every sec)  to 0.1 Hz (once 
every 10 sec) The response to single twitch depends on the frequency with 
which the individual stimuli are applied. A frequency of 0.1 Hz is generally 
used. 1Hz stimulation can be used during induction of anaesthesia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Train of four stimulation: 
 Introduced by Ali and associates during early 1970s20. Here four 
supramaximal stimuli are given every 0.5 sec (2 Hz). Dividing the 
amplitude of 4th response by the amplitude of 1st response provides TOF 
ratio. 
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In control, before giving muscle relaxant, all four responses are same. TOF 
ratio is 1.0 
 
Partial DP blockade  :  No fade occurs  
      TOF ratio is 1.0 
 
Partial NDP blockade :  Ratio decreases (fades) and is inversely          
proportional to the degree of blockade.  
 
 When used continuously each set of stimuli is repeated every 10th to 
20th second. 
 
 Loss of 4th response : 70% blockade   
 Loss of 3rd and 2nd response : 80-90% blockade  
 All four twitches absent : 100% blockade  
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Tetanic stimulation: 
 Very rapid delivery (30, 50, or 100 Hz) of electrical stimuli.  50Hz 
stimulation given for 5 sec is the most commonly used pattern. 
 
During normal neuromuscular  transmission and depolarizing block, 
the muscle response is sustained. There is no post tetanic potentiation.  
During a NDP block and phase II block after succinylcholine, the responses 
will not be sustained (fade occurs). Potentiation of post tetanic twitch  
occurs. 
 
 Fade to tetanic stimulation is a presynaptic event. On application of  
tetanic stimulation, large amounts of acetylcholine is released from  
immediately available stores in nerve terminal. 
  
 
 
  
 
 
 
 
 
 
 
 
 As this stores become depleted, the rate of acetylcholine release 
decreases and reaches an equilibrium between mobilization and synthesis 
of acetylcholine. 
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 Repeated used of tetanic twitch may cause  local reversal of block . It 
may also be painful in awake patients. 
 
Post tetanic count stimulation  
 Intense neuromuscular blockade is quantified here. Tetanic 
stimulation (50Hz for 5 sec) is applied and post tetanic response to single 
twitch stimulation given at 1Hz starting 3 sec after end of tetanic 
stimulation is observed.   
 
 
 Usually 12 -20 counts detect first response. 
 
 
 Very intense blockade: No response to tetanic or post tetanic 
stimulation 
 
  
  
  
  
 
 
 
 
 
 
 
 As intensity of block wears off the first response to post tetanic 
stimulation occurs, before response to TOF appears. As intense block wears 
off, more and more response to post tetanic stimulation occurs.   
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 During surgical blockade : First TOF appears and post tetanic count 
increases further.  
 
Double burst stimulation  
 This consists of two short bursts of 50Hz tetanic stimulation 
separated by 750msec. Duration of each square wave impulse in the burst is 
0.2msec. DBS with three impulses in each of two tetanic burst is most 
commonly used. 
 
 
 
 
 
 
 
 
Non paralyzed muscles  : Two short muscle contractions of equal    
       strength  
Partly Paralyzed muscles  : Second response is weaker than first (fade           
occurs) 
 
 DBS was developed with specific aim of allowing manual (tactile) 
detection of small amounts of residual blockade. 
 
Peripheral Nerve stimulators: 
 
 Used to monitor transmissions across NMJ. The stimulus should 
produce a monophasic and rectangular wave form. 
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Electrodes:   
 Electrical impulses are transmitted from stimulator to nerve by 
means of surface or needle electrodes. Normally disposal pregelled silver or 
silver chloride surface electrodes are used. Conducting area is  7-8 
diameter. 
 
 Skin is always cleaned properly and rubbed with abrasive before 
applying electrodes.  
 
 Needle should be placed subcutaneously but never in nerve.  Length 
of pulse should not exceed 0.2 -0.3 msec. Nerve stimulator should be 
battery operated, generating 60-70 mA, not more than 80mA.   Constant 
current is provided only when skin resistance ranges from 0Ώ to 2.5 kΏ  
 
Sites of nerve stimulation: 
 Any superficial peripheral motor nerve may be stimulated. Ulnar 
nerve is most commonly used. Median nerve, posterior tibial nerve, 
common peroneal and facial nerve are also used. In this study ulnar nerve 
was used . The electrodes  were applied at volar side of wrist. Distal  
electrode is placed 1 cm proximal to the point at which proximal flexion 
crease of wrist crosses the radial side of tendon to flexor carpi ulnaris. 
Proximal electrode is placed 2-5 cm proximal to distal electrode. 
 
 The electrical stimulation elicits finger flexion and thumb 
adduction12,13. 
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Recording of evoked responses : 
 
Five  methods of recording evoked response are  
1. Mechanomyography MMG : Measuring   evoked mechanical 
response of muscle.  
2. Electromyography   EMG : Measuring evoked electrical response of 
muscle. 
3. Acceleromyograply AMG : Measuring acceleration of muscle 
response. This technique is based on Newton ‘s 2nd law: force equals 
mass times acceleration . This is used in TOF watch SX 100, used in 
this study. 
4.  Piezoelectric NM monitor PzEMG : Measuring  evoked electrical 
response in a piezoelectric fibro sensor.  
5. Phonomyography PMG. 
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  PHARMACOLOGY 
                ROCURONIUM BROMIDE (ORG 9426) 
 
 Rocuronium is a monoquaternary aminosteroid non depolarizing 
neuro muscular  blocking  drug with intermediate onset of action.  
 
 It is a 2- morpholino 3 desacetyl , 16 n –allyl pyrrolidino derivative 
of vecuronium.  
 
 Structurally Roc resembles vecuronium except for the presence of a 
hydroxyl group rather than an acetyl group on the A- ring of steroid 
nucleus.  
 
 The presence of cyclic substituents other than  piperidine at the            
2 – and 16- positions resulted in a fast onset compound.  
 
 The methyl group attached to the quaternary N atom of vecuronium 
and pancuronium is replaced by allyl group, so it is 6 times less potent than 
vecuronium.  
 
 The replacement of acetyl ester attached to the A ring by a hydroxyl 
group has made Roc a stable solution18,21.  
Molecular structure: 
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Presentation:  
 A vial containing a clear, colourless to faintly yellow solution.  
Available in two quantities : 50 mg and 100 mg  
Product Esmeron  contains 10mg /ml of Rocuronium bromide as active 
ingredient. It also contains 
 
• Sodium acetate  
• Sodium chloride  
• Acetic acid  
• Water for injection  
• No preservative has been added.  
 
 
 
Storage : 
 
 Kept in refrigerator at 2-8 ° C and should not be frozen.  
 Esmeron can be stored outside refrigerator at a temperature of 30°C 
for a maximum of 12 wks. 
 Once kept outside it should not be placed back into the refrigerator.  
 
 
Routes of administration : 
 Intravenous bolus or infusion  
 Intramuscular  
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PHARMACODYNAMICS 
 
Dose:  
 
IV: 
ED 95     :  0.3 mg /kg 
Intubation at 60-90 sec   :  0.6 - 0.9 mg /kg  
Relaxation using (N2O/O2) :         0.3 -0.4 mg/kg  
(Vaporizer)    :  0.15- 0.2 mg/kg 
Maintenance    :  0.1-0.15 mg /kg 
Maintenance Infusion   :  9-12 µg/kg/ min 
IM: 
Infant   : 1mg/kg 
Child   : 1-8 mg/kg 
 
Mechanism of action : 
 Rocuronium  acts by combining with nAchRs without causing any 
activation of these ion receptor channels. It acts competitively with ACh at 
α subunits of postjunctional nAChRs without causing change in the 
configuration of these receptors. When large number of molecules of less 
potent Roc is used , greater number of molecules are available to diffuse 
into NMJ.   
 
Onset of maximum single twitch depression after the administration 
of 3 or 4  ED95 of Roc resembles onset of action of SCh 1mg /kg IV.  
 
Onset of action: 
Onset is time from injection to onset of maximal single twitch depression22.  
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IV: 
With narcotic    2 ED 95: 1.5-2 min  
With vaporizer    2 ED 95: 1.5 – 1.7 min  
Vaporizer     3 ED 95  : 40 sec – 80 sec 
     4 ED 95: 40 sec -70 sec 
 
Duration of action : 
Time from injection to return of single twitch height to 25% or 95% 
with 0.6 mg /kg is 25-35 min.  
  
Clinical duration : 
Time from injection to recovery of train of four ratio ≥0.7 to≥  0.9 
for 0.6mg/kg is 55-80 min. 
  
With narcotic: 0.6 mg /kg  :  36 min  
With vaporizer 0.9mg/kg  : 50-55 min  
With vaporizer 1.2mg/kg  : 70-80 min 
 
    
Recovery index : 
 Time from 25% return of single twitch height to 75% return of single 
twitch height  
 For 0.6 mg /kg is 14 min  
 
Maintenance dose:     
 Supplemental dose after intubation : 0.075 -0.15 mg / kg IV. 
 
Continuous infusion:  
 For loading dose of 0.6mg/kg, infusion is 9-12 µg/kg /min  
 
 Infusion rate is adjusted to maintain  90-95% twitch inhibition under 
N2O/O2 anaesthesia or to maintain 1 – 2 response to TOF. 
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PHARMACOKINETICS 
Distribution: 
 Neuromuscular blocking drugs due to their quaternary ammonium 
groups are highly ionized, water soluble compounds at physiological pH 
with limited lipid solubility. So volume of distribution is limited and similar 
to ECF volume (200 ml/kg). These do not easily cross lipid membrane 
barriers like blood brain barrier, renal  tubular epithelium, GI  epithelium or 
placenta. 
 
  So do not produce CNS effects, renal absorption is minimal, oral 
absorption ineffective and does not affect fetus.  
Volume of distribution for Roc is 0.3 liters / kg  
 
Metabolism: 
 Rocuronium is metabolized to 17 desacetyl  Rocuronium and 16 n 
desallyl Rocuronium.   
 
Clearance: 
 Roc is 4ml/kg /min 
  
Elimination: 
 Normal t ½ : 87 min  
 Roc is largely excreted unchanged in bile  
 Biliary excretion: 50-70% unchanged  
 Renal excretion: 10-25%  unchanged  
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Influence of age: 
 Age may affect pharmacokinetics of rocuronium  since total body 
water and function of organs involved in elimination of drugs diminish with 
increasing age.  
   In neonates and children, volume of distribution is increased and 
plasma clearance unchanged, causing longer elimination half life. 
 In children, volume of distribution is unchanged but clearance is 
increased, resulting in shorter half life and mean residual time23. 
 
Elderly:  
Duration prolonged due to decreased hepatic clearance 
 
Influence of obesity: 
 Rocuronium onset time is shorter and duration is prolonged in 
overweight patients when compared to normal and underweight people24.  
 
Hepatic diseases : 
 Increased volume of distribution of Roc, and results in longer 
duration of action of drug with  t ½  97min25. 
 
Renal failure: 
 Modest prolongation of action t ½ 97 min26  
 
Autonomic effect  
Autonomic ganglia : No effect  
Cardiac muscarinic receptor : Blocks moderately  
Hisamine release : None  
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Safety profile  
1. Cardiovascular effects:  
Like Vec, Roc at standard dose of 0.6 mg/kg does not produce 
significant changes in HR or MAP27. 
2. Histamine release : 
Roc does not produce significant histamine related symptoms with upto 
4 times ED95 dose27,12  
3. Anaphylaxis / anaphylactoid reaction:      
Has low risk of anaphylactoid reaction manifested as cutaneous 
erythema, hypotension, tachycardia. Bronchospasm may occur 
occasionally. 
4. Cholinesterase inhibition  
Lower than that of vec  
 
Drug interactions : 
Volatiles:  
 Enflurane and isoflurane potentiate the  effects of Roc. Halothane 
has less potentiation. N2O does not have any effect on depth of block28,29.       
  
IV Anaesthetics: 
Interactions have been reported when other NDNM blocking drugs 
are used. Roc with mivacurium results in synergistic activity. Studies 
suggest using subparalyzing  dose of Roc before SCh to  reduce 
fasciculation.  
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IV Antibiotics:  
NM blockade is prolonged when, Roc is used with amino glycosides, 
bacitracin, colistin, polymyxin, tetracycline and vancomycin30.  
 
Anticonvulsants : 
Chronic phenytoin therapy causes resistance to neuromuscular 
blockade activity probably due to receptor up regulation. Magnesium salts 
prolong NM blockade.  
 
Reversibility  
TOF ratio of 0.6-0.7 show adequate recovery of neuromuscular 
strength  
Block is antagonized with  
Neostigmine 0.04-0.07µg/kg  or sugammadex ORG 25969 2-8 mg/kg31 
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VECURONIUM BROMIDE 
 
Structure:  
Vecuronium is an N-demethylated derivative of pancuronium in 
which 2 piperidne substituent is not methylated. 
 
Vec is a monoquaternary  aminosteroid non depolarizing NMBD 
with intermediate duration of action .  At physiologic pH, the tertiary amine 
is largely protonated  similar to dTc.  
 
This modification  causes slight change in potency, a marked 
reduction in vagolytic properties, molecular instability  in solution causing  
short duration of action than pancuronium and increased lipid solubility 
causing greater elimination than pancuronium18. 
 
Molecular structure: 
 
  
 
 
 
 
Presentation : 
Vec is unstable is solution so supplied as a sterile, non pyrogenic, 
freeze dried,  lyophilized powder which is dissolved in sterile water before 
its use.  Addition of 1ml water for injection results in clear to almost clear 
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isotonic solution with pH of approximately 4 containing 4mg Vecuronium 
Bromide per ml.  
 
Reconstituted solution can be stored for 24hrs at room temperature 
15°C to 25°C in daylight.  
 
Solution can be prepared with : 
• 5%   glucose solution  
• 0.9% NaCl 
• RL solution 
• 5% glucose in RL solution 
• 5% glucose in 0.9% NaCl solution  
• Water for injection  
 
Packages :  
 Vecuronium bromide 4mg 
Package of 5 ampoules of each containing 4mg vec bromide  
 Vecuronium bromide 10mg 
Package of 5 vials of  each containing 10mg vec bromide  
Vecuronium bromide is supplied in a citrate phosphate buffered 
freeze dried form containing mannitol for tonicity adjustment  
 No preservative has been added     
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Routes of administration : 
IV bolus or infusion 
 
PHARMACODYNAMICS  
Dose : 
IV :  
ED 95      : 0.05 mg /kg 
Intubation dose    : 0.1-0.2 mg/kg 
Relaxation  (N2O /O2)  : 0.05mg /kg 
(Vaporizer )    : 0.03mg/kg 
Maintenance    : 0.02 -0.03 mg /kg 
Infusion    : 0.8 to 1µg/kg/min       
 
Mechanism of Action : 
Vecuronium acts by combining with  nAchRs without causing any 
activation of these ion receptor channels. It acts competitively with Ach at 
α subunits of postjunctional nAchRs without causing change in the 
configuration of these receptors. 
 
Onset of action : 
Onset is time from injection to onset of maximal single twitch depression32  
 
IV:  
With narcotic 2 ED95  : 3-5 min  
With vaporizer  2 ED95  : 2-4 min  
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Duration of action  
Time from injection to return of single twitch height to 25% or 95% 
with 0.1mg /kg  it is 25-35 min32. 
 
Clinical duration : 
Time from injection to recovery  of TOF ratio to ≥ 0.7 or ≥ 0.9 for 
0.1mg/kg is 40-80 min  
With narcotic 0.1mg/kg : 41 min  
With vaporizer 0.1 mg/kg : 44min  
 
Recovery index:  
Time from 25%  return of single twitch height to 75% return of 
single twitch  height 0.1mg/kg is 13 min.  
  
Maintenance dose : 
Supplemental dose after intubation  0.02mg/kg IV 
 
Continuous infusion : 
For a loading dose of 0.1 mg /kg , infusion is 0.8 -1 µg/kg /min.  
Infusion rate is adjusted to maintain 90-95% twitch inhibition under 
N2O/O2 anaesthesia or to maintain 1-2 response to TOF. 
 
PHARMACOKINETICS 
 
Distribution: 
NMBDs due to their quaternary ammonium groups and other linkage 
and methoxy groups have high degree of water solubility and slight lipid 
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solubility. Vecuronium is more lipid soluble than pancuronium due to 
absence of quaternizing methyl group at 2 position.  
 
Volume of distribution of vec is 0.27 liter /kg    
 
Metabolism : 
Vecuronium is more lipid soluble than pancuronium. It  undergoes 
metabolism 2-3 times more than Pan. Vec is taken up by liver by carrier 
mediated transport system and is desacetylated at 3- position by liver 
microsomes.  
 
12% of  vec is cleared  as 3- desacetyl vec.  
30-40% cleared in bile as parent compound.  
 
Other metabolites are.  
 
17 desacetyl vec and  
3,17  desacetyl vec  
Principal metabolite 3- desacetyl vec is a potent NMBD, about 80% 
of vecuronium.  3- desacetyl  vec  has lower plasma clearance  and longer 
duration than vec.  
 
Clearance : 
Vecuronium  is 3-6 ml/kg /min 
3 desacetyl vec is 3.5ml/kg /min  
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Elimination:  
 Normal elimination t ½ 50-110 min  
 40-75 % excreted unchanged in bile  
 15-25% excreted unchanged in urine  
 20-30% hepatic degradation  
 
Hepatic disease : 
Prolonged elimination half life and increased duration of action. 
Elimination t ½ 49-192 min.  
 
Renal failure : 
Elimination half life of both vecuronium and 3- desacetyl 
vecuronium is prolonged leading to decreased clearance of drug. Increased 
plasma concentration of 3 desacetyl vec contributes to prolonged skeletal 
muscle paralysis after prolonged infusion in renal failure patient.  
Elimination of  t ½ = 80-150 min33.  
 
Cumulative effects : 
Vec has large volume of distribution and tissue uptake. After a single 
dose of vecuronium, the plasma concentration  decreases rapidly due to 
redistribution from central to peripheral compartment. With subsequent 
doses, the vecuronium present in peripheral tissue compartment limits  the 
distribution and also the rate of decrease in plasma concentration of drug 
causing a cumulative effect.   
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 Autonomic effects : 
Autonomic ganglia   :  None  
Cardiac muscarinic receptors  : None  
Histamine release    :  None  
 
Pediatric patients: 
Onset in more rapid in infants than adults. Duration of action is 
longest in infants and shortest in children34.  
   
Vec 
mg/kg 
Onset of action 
(min) 
Duration 
Min 
Infants   0.07 1.5 73 
Children  0.07 2.4 35 
Adults 0.07 2.9 54 
  
  High cardiac output in infants speeds onset of Vec and immature 
enzyme system prolongs the duration of action36. 
 
Elderly patients:  
 Prolonged duration of blockade  
 Volume of distribution and plasma clearances are decreased.  
 
Pregnancy: 
 Insufficient amount of drug cross placenta to produce significant 
effects in fetus. Clearance of Vec is accelerated during late pregnancy due 
to stimulation of hepatic enzymes by progesterone and large fluid shift 
during pregnancy. Duration of action is  prolonged in immediate post 
partum period.  
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Obesity  
 Duration of action of Vec is prolonged in obese patients35   
 
Safety profile : 
1. Cardio vascular system:  
 Vec at doses of 0.1 - 0.15 mg /kg does not produce any significant 
changes in heart  rate or MAP37,38.  
 
2. Histamine release : 
 Administration of clinical doses of vec does not produce any 
significant histamine release27. 
 
3.  Anaphylactic   / Anaphylactoid reactions:  
 Rare instances of hypersensitivity reactions  may occur like 
bronchospasm, hypotension, tachycardia with erythema or utricaria.  
  
Drug interactions: 
Inhalational anaesthetics : 
 Volatiles like enflurane, isoflurane and halothane enhance Vec 
induced NM blockade. Potentiation is more prominent with enflurane and 
isoflurane39.  
 
IV Anaesthetics: 
Use of other NDNM blocking agents like pancuronium, metocurine 
along with Vecuronium may show additive effect. Use of sub paralyzing 
dose of vec before succinlycholine, to attenuate some side effects of 
succinylcholine have not been  sufficiently studied. 
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  IV Antibiotics : 
 NM blockade of Vec is prolonged  when drugs like aminoglycosides, 
tetracycline, bacitracin, polymyxin B, colistin are used30.  
 
Others:  
 Electrolyte imbalance, adrenocortical insufficiency alter Vec induced 
NM blockade. Magnesium  salts prolong Vec blockade. 
 
Reversibility: 
 Vec induced NM blockade can be reversed with use of neostigmine, 
physostigmine or edrophonium along with glycopyrrolate or atropine.   
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REVIEW LITERATURE 
1. Lin PL, Liu CC, Fan SZ, Chao A, Shin SC, Tai YT et al., in Acta 
Anesthesiol Sin. 1997 have compared the neuromuscular action of 
Rocuronium with Vecuronium, and concluded that Rocuronium 
0.6mg/kg  provides more rapid onset of action than that of 
vecuronium 0.1mg /kg and also provides good to excellent intubation 
conditions.  
2. England AJ, Margarson MP, Feldman SA et al., in Anesthesia 1997 
have studied the tracheal intubation 1min after giving Rocuronium  
and  vecuronium.  The patients received twice ED95 or equipotent 
mixture of both vecuronium, alone and in combination. The 
intubating conditions in Rocuronium and the mixture groups were 
similar and both groups significantly better than vecuronium group.  
3. Magorian T, Flannery KB, Miller RD et al., of Department of 
Anesthesia, University of California have compared three doses of 
Rocuronium (0.6, 0.9 and 1.2 mg/kg), Vecuronium (0.1 mg/kg)  and  
Succinylcholine (1.0mg/kg).They found that onset time of patients 
receiving 0.9mg /kg and 1.2mg /kg and Sch (1.0mg /kg) were 
similar. Onset time for groups  Roc 0.6mg /kg and Vec 0.1 µg/kg 
were significantly longer. Clinical duration was prolonged with 
0.9µg/kg and 1.2µg/kg groups. It was concluded that there is a dose 
dependent decrease in onset time with Rocuronium    
4. Smith I, Saad RS et al., Keele University, in Br. J Anaesth, 1998 
have compared intubating conditions after Rocuronium or 
Vecuronium, with the timing of intubation judged by clinical criteria. 
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They found that Rocuronium 0.6mg/kg resulted in significantly 
better intubating conditions compared with Vecuronium 0.1mg with 
no significant  reduction in the hemodynamic response. They also 
concluded that earlier  intubation  should be possible by careful 
timing or by neuromuscular monitoring.    
5. Shingu K, Masuzawa M, Omote K, Namiki A et al., of Department 
of Anesthesiology, Kansai Medical University in Masui 2006 have 
done a comparative study between Rocuronium 0.6mg /kg and 0.9 
mg/kg with Vecuronium 0.1mg/kg in Japanese patients. The onset 
time of 0.6 and 0.9 mg/kg were 84.6 and 77.1 sec respectively which 
showed a significant difference from that of Vecuronium  0.1mg /kg  
125.7 sec.  Clinical duration of 0.6, 0.9 mg/kg of Roc and 0.1mg /kg 
of Vec were 53.4 , 73.4 and 59.9min. It was concluded that Org 9426 
showed more rapid onset time than Vecuronium,  and  similar 
clinical duration for equipotent doses in Japanese patients.  
6. Shorten GD, Uppington J, Comunale ME, of Department of 
Anesthesia and Critical Care, Beth Israel hospital, Boston in Eur.  J 
Anesthesia, 1998 had studied  the changes in plasma concentration of 
catecholamines and hemodynamic effects of Rocuronium and 
Vecuronium in elderly patients. The study was compared after 
administration of Roc 0.9mg/kg and Vecuronium 0.12mg/kg in 
elderly patients.  It was found that BP and HR were similar in two 
groups throughout the study. There was no significant change in 
either plasma noradrenaline or adrenaline concentration is either 
groups after muscle relaxant or during tracheal intubation.  
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7. Bartkowski RR, Witkowski TA, Azad S et al, of Department of 
Anethesiology, Thomas Jefferson University, Philadelphia, had 
compared the onset, maximal neuromuscular block and duration of 
Rocuronium with Vecuronium, and Atracurium during enflurane 
anaesthesia. 60 patients received 80,100,120 or 160, mcg/kg 
Rocuronium. Rocuronium’s onset time was significantly faster than 
either of the other two muscle relaxants. Time to 90% of final block 
was 1.35 min for Roc, 3.06 min for Atracurium and 3.7 min for 
Vecuronium. The speed of onset was inversely related to their 
potency.   
8. Smith CE, Kovach B, Polk JD et al., of Metro Health Medical 
Centre, Cleveland in Air Med J.2002 had studied prehospital  
tracheal intubating conditions during rapid emergency intubation 
using Rocuronium and Vecuronium. In this study patients  received 
equipotent doses of Roc 1.0mg/kg and Vec 0.15mg /kg. They 
concluded that no cardiovascular differences occurred between 
groups after intubation. Tracheal intubating conditions and clinical 
evidence of complete neuromuscular blockade was better in Roc 
1.0mg /kg than Vec 0.15mg /kg . 
9. Naguib M, Samarkandi AH, Bakhamees HS et al., Department of 
Anesthesia, King Saud University, Riyadh in Br J Anaesth. 1995 had 
studied histamine-release hemodynamic changes produced by 
Rocuronium 0.6mg /kg, Vecuronium 0.1mg/kg, Mivacurium 0.2mg 
/kg, Atracurium 0.6mg/kg, and Tubocurarine 0.5mg/kg. Venous 
blood samples were obtained 1 min before and after induction and 1, 
3, 5 min after giving the NM blocking drug. Mivacurium, 
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Atracurium and Tubocurarine caused 370%, 234% and 252% at 
1min and 223%, 148% and 157% at 3min increase in plasma 
histamine concentrations respectively. Rocuronium and Vecuronium 
groups had no significant changes in either plasma histamine 
concentrations or hemodynamic variables.    
10. McCoy EP, Maddineni VR, Elliott P et al., Department of 
Anesthesia, Queen’s University, Northern  Ireland  compared the 
hemodynamic effects of Rocuronium 0.6mg/kg and Vecuronium 
0.08mg/kg during fentanyl anaesthesia in elective CABG patients. 
They observed that changes in heart rate, mean arterial pressure, 
systemic vascular resistance,  mean pulmonary artery pressure in 
both Rocuronium and Vecuronium groups were insignificant 
(p<0.05). The absolute values of all variables were within acceptable 
clinical limits. They also observed no evidence of histamine release 
in any patient.  
11. Booth MG, Marsh B, Bryden FM et al., of Division of Anesthesia, 
Royal Infirmary, Glasgow had compared the pharmacodynamics of 
Rocuronium 0.6mg /kg and Vecuronium 0.1mg /kg during halothane 
anesthesia. The onset time, duration 25, duration 75 and TOF 70 
were measured. The onset of neuromuscular blockade following 
Rocuronium was more rapid than Vecuronium (P=0.0001). All other 
pharmacodynamic parameters were similar.  
 
12.  B.B.Kushwaha, B.K.Behary, P.Rajan et al., in Journal of 
Anesthesiology Clinical Pharmacology 2008 ; had compared the 
intubating conditions and cardiovascular effects after administration 
of Rocuronium and Vecuronium in children. Patients were randomly 
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allotted into three groups each receiving Group I Vecuronium 
0.1mg/kg, group II Rocuronium 0.6mg/kg and group III Rocuronium 
0.9 mg/kg. They had found that Vecuronium 0.1/kg has onset time of 
120 seconds. 0.9 mg/kg Rocuronium provides excellent intubating 
conditions at 60 seconds than 0.6mg /kg at 90 seconds. They also 
concluded that hemodynamic parameters remained in clinically 
acceptable limits in all three groups.  
 
13. De Mey JC, Debrock M, Rolly G. et al., Department of 
Anesthesiology, University Hospital, Belgium had studied the 
evaluation of the onset and intubating conditions of Rocuronium 
bromide. Patients received three doses of Rocuronium 0.6, 0.75 and 
0.9 mg/kg after supramaximal TOF stimulation of the ulnar nerve, 
and intubation conditions, onset time, recovery to 25% were 
determined. They concluded that in general, intubation conditions 
were excellent or good. They also concluded that onset time was 
longer (P<0.01) in 0.6mg/kg group compared to 0.9mg/kg group. 
The recovery to 25% was shorter in the 0.6mg/kg group (P<0.01) 
 
14. Cooper RA, Mirakhur RK, Maddineni VR et al, of Department of  
Anesthetics, Queen’s University of Belfast, had studied the 
neuromuscular effects of Rocuronium bromide (ORG 9426) 
0.6mg/kg and 0.9mg/kg during fentanyl and halothane anesthesia. 
Neuromuscular block was monitored using mechanomyography and 
train of four stimulation. They found that mean onset time for 
0.6mg/kg in fentanyl and halothane groups were 58 sec and 59 sec. 
Onset time for 0.9mg/kg on were 47 sec and 44 sec for fentanyl and 
halothane group. The time to recovery of TOF to 0.7 were 83 min 
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and 93 min in 0.9 mg /kg fentanyl and halothane groups, and in 
0.6mg /kg groups were 55 min and 60 min. 
15. Bencini A, Newton DE et al., is Br Jr Anaesth had studied the rate  of  
onset of good intubating conditions, respiratory depression and hand 
muscle paralysis after Vecuronium. They had observed the NM 
blockade of adductor pollicis muscle following 0.1, 0.15 and 
0.2mg/kg and compared with the intubating conditions and 
respiratory paralysis. Ideal intubating conditions were attained 3.5 
min and 2.5min after injection of Vec 0.1 mg/kg and 0.2mg/kg 
respectively. They had concluded that increasing the dose of 
Vecuronium form 0.1mg/kg to 0.2mg/kg prolonged the duration of 
action significantly from 21 to 48 min but did not shorten the onset 
of time significantly nor  prolong the rate of recovery.  
16. Andrews JI, Kumar N, van den Brom RH, et al., of Department of 
Anesthesia, University of Newcastle had conducted a large 
randomized trial of Rocuronium with Succinylcholine in rapid 
sequence induction of anaesthesia along with propofol. 349 patients 
were randomized to receive Rocuronium 0.6 or 1mg /kg or 
succinylcholine 1.0mg/kg. They had observed that Rocuronium 1.0 
mg/kg provided superior intubating conditions compared with   
Rocuronium 0.6mg/kg and the incidence of clinically acceptable 
intubating condition with Rocuronium 1.0mg/kg and succinylcholine 
1.0mg/kg was 93.2% and 97.1% respectively. They had concluded 
that Rocuronium 1.0mg/kg given along with propofol in a rapid 
sequence induction is clinically equivalent to succinylcholine 1.0mg 
/kg.  
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17. McCourt KC. Salmela L, Mirakhur RK, et al.,  of Department of   
Anaesthetics, Queen’s University of Belfast, UK had compared 
Rocuronium and suxamethonium for use during rapid sequence 
induction of anaesthesia. Patients were randomized to receive 
Rocuronium 0.6 or 1.0mg/kg and Suxamethonium 1.0 mg/1kg. The 
results showed that the intubating conditions were significantly 
superior with Roc 1.0mg/kg than Roc 0.6mg/kg (p<0.01). The 
comparison between Rocuronium 1.0mg/kg and Suxamethonium 1.0 
mg/kg showed no significant difference in incidence of  intubation 
(96% and 97%) respectively. They thus concluded that Rocuronium 
1.0mg/kg can be used as an alternative to Suxamethonium 1.0mg/kg 
but the clinical duration of Rocuronium is 50-60 min. 
 
18. Wierda JM, Hommes FD, Nap HJ, van den Broek L, et al., of 
Department of Anesthesiology, University Hospital of Groningen, 
The Netherlands had studied the time course of action and intubating 
conditions following Vecuronium, Rocuronium and Mivacurium. 
The patients randomly received 2 x ED 95 of either Vecuronium, 
Rocuronium or Mivacurium. Average onset time of Rocuronium 
(172 sec) and Vecuronium (192 sec) were significantly shorter than 
Mivacurium (229 sec). The clinical duration for Mivacurium (13 
min) was significantly shorter than Vecuronium (33 min) or 
Rocuronium (28 min). 
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MATERIALS  AND  METHODOLOGY 
 
Adult patients of both sexes in the age group of 15-50 yrs belonging 
to ASA I / II category and their weight ranging 40-80 kg posted for various 
surgeries requiring general anaesthesia at Department of General Surgery, 
Department of Surgical Gastroenterology, Department of Plastic Surgery, 
Department of Urology  and Department of Eye, Nose and Throat, Govt. 
KMCH, formed the study group. 
 
This study was designed as randomized, prospective study. The study 
was performed after obtaining the  institutional ethical committee approval. 
Pre study assessment was done, procedure explained and informed consent 
obtained and patients were randomly allocated into 3 groups requiring  GA. 
 
Groups : 
1. Group I   :15 patients receiving  Inj. Rocuronium Bromide 0.6 mg/kg 
2. Group II  :15 patients receiving Inj. Rocuronium  Bromide 0.9 mg/kg 
3. Group III :15 patients receiving Inj. Vecuronium bromide 0.1  mg/kg 
 
 
Patient Selection : 
Inclusion Criteria : 
 45 patients of ASA grade I & II 
 Age 15-50 yrs 
 Both sex 
 Requiring General Anaesthesia with Endotracheal Intubation. 
 Elective Surgery 
 Without any comorbid illness.  
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Exclusion criteria: 
 Having any allergy to narcotics or neuromuscular blocking  drug. 
 Patients on any other treatment which might interfere with action of 
 NM blocking drugs 
 Pregnant patients 
 Having neuro muscular diseases 
 Having preop airway or intubation problems. 
 
Drug Treatment: 
Group A : ROC 0.6 mg /kg  
Group B: ROC 0.9 mg /kg 
Group C:  VEC 0.1 mg/kg 
 
Monitoring : 
 Pulse oximetry  
 NIBP 
 ECG 
 TOF-WATCH SX 100 
 Temperature Monitor  
 
TOF WATCH SX : 
 Has two optional calibration modes. 
 Acceleration transducer, temperature sensor and cable for surface 
electrodes present. 
 Nerve stimulation attained at low current  
 Display of data in computers. 
 Train of four with programmable repetition time. 
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Methodology 
• 45 patients were randomized into three groups of 15 each. 
• Premedication : 
Patients premedicated  with Inj. Glycopyrrolate  0.2 mg IV,  Inj. 
Fentanyl  2 mcg/kg IV 15 min before  induction.  
• Preoxygenation : 
      Done with 100% O2 for 3 min 
 
Preinduction : 
PR, BP, ECG monitors connected  
IV line started 
TOF – WATCH SX 100 nerve stimulator attached. 
 
Induction : 
• Pt. induced with Inj. Propofol 1.5mg/kg IV 
• Loss of eyelash reflex observed. 
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• TOF WATCH SX turned on. Once the current and twitch height 
were standardized, instrument switched to TOF mode where supra  
maximal TOF stimuli is applied to ulnar nerve every 15 sec. 
• Calibration and baseline responses obtained before administering 
NM blocking drug. 
 
Muscle Relaxation & Intubation  : 
Group I  : Received Inj. Rocuronium 0.6mg/kg 
Group II  : Received Inj. Rocuronium 0.9 mg/kg 
Group III  : Received Inj. Vecuronium 0.1 mg/kg 
 
• Bolus dose given as IV over 5 sec in rapidly running IV line and time 
noted 
• TOF WATCH SX showed TOF ratio as percentage and results 
recorded at 30 sec interval. 
 
Time to Maximum Blockade  
• Time interval between administration of dose of relaxant and 
disappearance of all four twitches in TOF monitor.  
• Intubation was done when TOF ratio was 0%.  
• Anaesthesia  maintained with O2 :N2O and 0.8% Isoflurane 
• The intubating conditions and degree of neuro muscular blockade 
assessed at 1,2,3 and 4 min with 30 sec interval. 
• Time to maximum blockade and duration of action were also 
assessed.  
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OBSERVATION 
 
TOF % at ‘0’ sec 
 
 
 
 
 
 
  P =0.577    Not significant  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, TOF % at ‘0’ sec was not  significant in any group. 
S.No N Mean Std. Deviation Std. Error 
1 15 104.73 5.365 1.385 
2 15 103.40 3.225 .833 
3 15 105.27 5.958 1.538 
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TOF % at ‘30’ sec 
 
S.No N Mean Std. Deviation Std. Error 
1 15 91.00 2.903 .750 
2 15 68.67 8.006 2.067 
3 15 94.00 4.943 1.276 
 
P= 0.0000 <0.005   Significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, TOF % at ‘30’ sec was found to be  significant in 
group 2 than other two groups.  
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TOF % at ‘60’ sec 
 
S.No N Mean Std. Deviation Std. Error 
1 15 74.67 6.008 1.551 
2 15 23.40 20.170 5.208 
3 15 83.40 5.488 1.417 
      
    P: 0.0000    <0.005    Significant  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, TOF% at 60 sec was found to be significant in group 2 
than other two groups.  
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TOF % at ‘90’ sec 
 
S.No N Mean Std. Deviation Std. Error 
1 15 53.20 6.930 1.789 
2 1 
14 
19.00 
0.00 
. . 
3 15 66.33 7.228 1.866 
         
  P: 0.000   <0.005   Significant  
 
 
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, TOF% at 90 sec was found to be significant in group 2 
than other two groups. 
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 TOF % at ‘120’ sec 
 
 
 
 
 
 
 
 
P: 0.000   <0.005  Significant  
 
 
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, TOF% at 120  sec was found to be significant in group 2 
than other two groups. 
 
 
 
S.No N Mean Std. Deviation Std. Error 
1 15 27.73 10.257 2.648 
2 
1 
14 
10.00 
0.00 
. . 
3 15 47.20 8.954 2.312 
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TOF % at ‘150’ sec 
 
 
S.No N Mean Std. Deviation Std. Error 
1 14 
1 
11.29 
0.00 
9.809 2.622 
2 1 
14 
10.00 
0.00 
. . 
3 15 24.27 8.489 2.192 
 
P: 0.0002   <0.005   Significant  
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, TOF% at 150 sec was found to be significant in group 2 
than other two groups. 
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TOF % at ‘180’ sec 
 
 
S.No N Mean Std. Deviation Std. Error 
1 13 
1 
1 
1.62 
10.00 
0.00 
3.948 1.095 
2 1 
14 
10.00 
0.00 
. . 
3 13 
2 
10.00 
0.00 
6.904 1.915 
 
 
P: 0.003   <0.005   Significant  
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, TOF% at 180 sec was found to be significant in group 2 
than other two groups.  
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TOF % at ‘210’ sec 
 
 S.No        N   Mean  Std. Deviation   Std. Error 
1 1 
14 
10.00 
0.00 
. . 
2 1 
14 
10.00 
0.00 
. . 
3 1 
14 
10.00 
0.00 
. . 
 
P: 0.637    > 0.005    Not Significant  
 
 
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, TOF% at 210  sec was found to be ‘o’ in all three group 
and hence not significant.  
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TOF % at ‘240’ sec 
 
S.No N Mean Std. Deviation Std. Error 
1 5 
10 
2.00 
0.00 
4.472 2.000 
2 15 .67 2.582 .667 
3 15 .67 2.582 .667 
 
P: 0.637   >0.005   Not Significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, TOF% at 240 sec was found to be ‘o’ in all three group 
and hence not significant.  
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TOF %  after ‘5’ min 
 
S.No N Mean Std. Deviation Std. Error 
1 15 .67 2.582 .667 
2 15 .67 2.582 .667 
3 15 .67 2.582 .667 
 
P: 1.000 > 0.005      Not significant  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, TOF% after 5 min was found to be ‘o’ in all three groups 
and hence not significant.  
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Time to maximum blockade 
 
 
S.No N Mean Std. Deviation Std. Error 
1 14 171.43 18.337 4.901 
2 14 77.14 15.407 4.118 
3 14 199.29 14.917 3.987 
 
P: 0.000   <0.005   Significant  
 
 
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, time to maximum blockade or onset of action was found to 
be significant in group 2 than other two groups     
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Duration of Action 
 
 
 S.No     N  Mean    Std. Deviation  Std. Error 
1 15 36.60 4.014 1.036 
2 15 48.20 7.608 1.964 
3 15 38.93 1.580 .408 
 
    P: 0.000   <0.005   Significant  
 
 
 
 
 
 
 
 
 
 
 
 
Using ANOVA, duration of action was found to be significant in Group 2 
than other two groups.  
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OBSERVATIONS OF HEART RATE 
 
 
 
 
 
 
 
 
 
P>0.005 in all three groups  
Hence heart rate changes are Not Significant. 
                MEAN  HEART  RATE  PER  MIN 
SEC GROUP I 
ROC 0.6 
GROUP II 
ROC 0.9 
GROUP III 
VEC 0.1 
0 84.60 82.40 85.47 
30 84.67 82.40 86.13 
60 85.13 83.13 85.67 
90 85.93 85.44 85.93 
120 87.13 87.32 88.20 
150 87.27 87.22 88.20 
180 86.10 83.15 88.20 
210 81.00 83.13 88.60 
240 81.00 83.12 88.60 
DL 92.60 88.13 91.67 
After 5 min 86.07 83.47 86.33 
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                 OBSERVATIONS OF  MEAN SYSTOLIC BP 
 
                       MEAN SYSTOLIC BP   mm Hg   
     SEC 
 
GROUP I 
ROC 0.6 
GROUP II 
ROC 0.9 
GROUP III  
VEC 0.1 
SIGNIFICANCE 
0 120.80 119.33 119.60  
30 120.80 119.33 119.60 0.876 
60 121.00 120.53 119.60 0.895 
90 122.80 121.78 119.67 0.526 
120 124.07  119.67 0.171 
150 124.73  121.20 0.307 
180 125.80  121.27 0.243 
210 122.50  121.50 0.580 
240   110.00  
DL 129.33 125.40 125.00 0.320 
AFTER 
5 MIN 
122.53 120.73 120.40 0.748 
 
 
P >0.005   Not   Significant  
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OBSERVATIONS OF MEAN DIASTOLIC BP 
 
                       MEAN DIASTOLIC BP   mm Hg   
SEC 
GROUP I 
ROC 0.6 
GROUP II 
ROC 0.9 
GROUP III 
VEC 0.1 
SIGNIFICANCE 
0 74.26 74.67 73.33 0.886 
30 74.27 74.67 73.33 0.886 
60 74.33 75.33 73.33 0.775 
90 75.93 78.89 74.07 0.234 
120 77.33  76.33 0.728 
150 77.47  76.40 0.720 
180 78.60  76.40 0.647 
210 78.60  77.40 0.506 
240 78.60  77.40  
DL 83.20 79.47 80.27 0.407 
AFTER 
5 MIN 
76.93 75.73 74.33 0.640 
 
 
P >0.005  Not  Significant  
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              SBP & DBP – OF GROUP I ROC 0.6 
 
 
 
SBP & DBP – OF GROUP II ROC 0.9 
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SBP & DBP – OF GROUP III VEC 0.1 
 
 
 
 Systolic and diastolic BP variations before giving drug, at the time of 
giving drug, during laryngoscopy and 5 min after laryngoscopy were not 
significant in all three groups.  
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DISCUSSION 
 
The use of neuromuscular blocking drugs has its origin in  South 
American Indian’s arrow poison or curares. Initially  d-tubocurarine  was 
used but increased mortality led to the search of other neuromuscular 
blocking drugs. Succinylcholine  introduced by Theselff and Foldes in 1952 
has changed the  anaesthetic practice due to its rapid onset and short 
duration  facilitating rapid tracheal intubation. 
 
Later in 1967, Baird and Reid first reported the use of aminosteroid 
Pancuronium which lacked ganglionic blocking and histamine releasing 
properties and also was vagolytic. Since then numerous non depolarizing 
muscle relaxants like pipecurium,  doxacurium, atracurium, cis atracurium, 
rapacuronium,  vecuronium and rocuronium were introduced, each with an  
advancement over their predecessor. 
 
 In this study, non depolarizing, intermediate acting, steroidal 
compounds Rocuronium and Vecuronium were chosen which  provide 
rapid onset, better cardiovascular stability, nil histamine  release, and their 
neuromuscular function was monitored using TOF-WATCH SX 100. 
 
 Rocuronium, a non depolarizing, aminosteroid has rapid  onset with 
intermediate duration of action41,42,43,44. The changes in the  steroid nucleus 
has made it a more  stable solution and 6-10 times  less potent than 
Vecuronium. The speed of onset is inversely  proportional to the potency of 
non depolarizing neuromuscular  blockers53. The onset time or time to 
maximum blockade of 3 ED95  (0.9 mg/kg) and 4 ED95 (1.2mg/kg) of 
Rocuronium are 1.3 min and 0.9 min respectively47,49. High dose regime 
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also increases the  duration of action from 53 min (0.9mg/kg) to 73 min 
(1.2mg/kg) 42,51.  
 
Low potency neuromuscular blockers like Rocuronium have  more 
molecules to diffuse from central compartment into the effect  
compartment, where they act promptly. Weaker binding of low  potency 
drugs to receptors prevent buffered diffusion and more  molecules occupy 
receptors causing rapid onset. Potent drugs  undergo buffered diffusion 
causing repetitive binding and  unbinding to receptors, so onset time is 
prolonged53. Rocuronium 0.9mg/kg provides excellent intubating 
conditions and rapid  tracheal intubation, and 0.6mg/kg is the intubating 
dose, hence  these two doses were used in this study42.  
 
The onset of blockade is much more rapid in laryngeal  adductors, 
diaphragm and masseter than in adductor pollicis. The  pattern of blockade 
in orbicularis oculi is similar to that in larynx.  But since adductor pollicis 
is most commonly used to monitor  neuromuscular blockade, Ulnar Nerve 
was used to monitor in this  study54. 
 
 Vecuronium is a demethylated derivative of Pancuronium  having 
slight change in potency, marked reduction in vagolytic  properties, not 
stable in solution and increased lipid solubility. The  onset of action of 2 
ED95 (0.1mg/kg) is 3-5 min and the duration  of action is 25-35 min. Since 
studies have shown that increasing  the dose of Vecuronium does not 
significantly shorten the onset of  action, only 2 ED95 (0.1mg/kg) dose is 
used in this study32,52. 
 
Shingu et al have studied that the onset time of 0.6, 0.9 mg/kg  of 
Roc, and 0.1 mg/kg of Vec were 84.6 sec, 77.1 sec and 125.7 sec  
78 
 
respectively. The clinical duration of 0.6, 0.9 mg/kg of Roc and     0.1 
mg/kg of Vec were 53.4, 73.4 and 59.9 min respectively. 
 
Magorian et al have studied and concluded that onset time of  
patients receiving Roc 0.9 mg/kg, 1.2 mg/kg and Succinylcholine  
1.0mg/kg were similar whereas the onset time of Roc 0.6 mg/kg  and Vec 
0.1 mg/kg were significantly longer. The clinical duration  was longest in  
Roc 0.9 mg/kg and 1.2 mg/kg groups. 
 
 Andrews et al had studied the effects of Roc 0.6 mg/kg, 1 mg/kg  and 
Succinylcholine 1 mg/kg and concluded that Roc 1mg/kg along  with 
propofol provided superior intubating conditions and clinically  equivalent 
to Sch 1.0 mg/kg. 
 
 Bencini et al had studied the effects of Vecuronium 0.1, 0.15 and  0.2 
mg/kg and found that onset time for 0.1 and 0.2 mg/kg were 3.5  min and 
2.5 min. They concluded that increasing the dose of Vec from 0.1 to 0.2 
mg/kg prolonged the dration of action significantly from  21 to 48 min, but 
did not shorten the onset time significantly. 
 
 Shorten et al had studied the plasma concentration of  
catecholamines and hemodynamic effects of patients receiving Roc  
0.9mg/kg and Vec 0.1 mg/kg. They concluded that hemodynamic  variables 
were similar in both groups and no significant change in  plasma 
catecholamine concentration in any group. 
 
 In this prospective, randomized, comparative study, 45 patients  
satisfying selection criteria underwent general anesthesia using Roc  0.6, 
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Roc 0.9 and Vec 0.1 mg/kg. The onset of action, which was the  
disappearance of all four twitches and TOF ratio 0 %, the duration of  
action and hemodynamic variables were assessed. 
 
 The onset of action or the time to maximum blockade was 
significantly faster in Group II (Roc 0.9mg/kg) than Group I (Roc  
0.6mg/kg) or Group III (Vec 0.1mg/kg). The onset of action was 60-90  sec 
in Group II, 150-180 sec for Group I and 180-210 sec for group III  as 
shown by Bartkowski et al, B.B.Kushwaha et al and Magorian et al. 
  
TOF % was between 0-20% at 60-90 sec in Group II (Roc 
0.9mg/kg); 11% at 150-180 sec in Group I (Roc 0.6mg/kg) and 0-1%  in all 
the groups at 180-210 sec. This shows that the speed of onset is inversely 
proportional to the potency. So large dose of a low potent drug, 
Rocuronium 0.9mg/kg provides faster onset than other two  groups. 
 
   The duration of blockade was significantly longer in Group II  (Roc 
0.9mg/kg) 48.20 min than Group I (Roc 0.6mg/kg) 36.6 min and  Group III 
(Vec 0.1mg/kg) 38.93 min. These results were consistent  with the studies 
done by Shingu et al, Cooper et al, McCourt et al. 
 
 The hemodynamic variables like pulse rate, systolic and diastolic  BP 
were not significantly altered in all the three groups. There were no 
significant changes in the hemodynamic variables during preop, at the   
time of injecting the drug, during laryngoscopy and 5 min after  
laryngoscopy in all the three groups (Roc 0.6, Roc 0.9 and Vec 0.1  mg/kg) 
as shown by Shorten et al and Naguib et al.  
No adverse reaction or complication occurred in any of the three 
groups. 
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SUMMARY 
 
1. Group II patients receiving Inj.Roc 0.9 mg/kg showed excellent  
intubating conditions between 60 – 90 sec. 
2. Group I patients receiving Inj.Roc 0.6 mg/kg had maximum      
blockade between 150–180 sec and Group III patients receiving   
Inj.Vec 0.1 mg/kg had maximum blockade between 180-210 sec. 
3. The mean duration of action in Group II (Inj.Roc 0.9) was 48 min. 
4. The mean duration of action in Group I (Inj.Roc 0.6) was 37 min  
and in Group III (Inj.Vec 0.1) was 39 min. 
5. There were no significant changes in hemodynamic variables in  all 
three groups. 
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CONCLUSION 
 
 In conclusion, Roc 0.9 mg/kg provides excellent intubating 
conditions with rapid onset of action, with longer duration of action and  no 
significant hemodynamic changes when compared with Roc 0.6  mg/kg and 
Vec 0.1mg/kg and hence can be used as an ideal intubating dose. From the 
above mentioned study it can also be concluded that Roc 0.9mg/kg can be 
used for rapid sequence intubation in the place of depolarizing muscle 
relaxants like succinylcholine.   
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PROFORMA 
 
 
NAME:    AGE/SEX:   IP NO. 
 
DATE:    Wt:    GROUP: 
 
DIAGNOSIS: 
 
SURGERY: 
 
BRIEF HISTORY: 
 
 
COEXISTING ILLNESS: 
 
EXAMINATION: 
   
   PR:    CVS: 
 
   BP:    RS: 
 
   RR:    AIRWAY: 
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INVESTIGATIONS: 
Hb:    BLOOD UREA: 
 
  URINE ALB:  SUGAR: 
 
  SUGAR:             Sr. CREATININE: 
 
  ELECTROLYTES        Na:    K: 
INTUBATION DETAILS: 
 
   Premedication: 
 
Preoxygenation: 
 
  Induction: 
 
Muscle Relaxant: 
 
Intubation Score: 
 
Confirmation of ETT: 
 
No. of attempts at intubation: 
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S NO GROUP NAME  AGE SEX IP NO. WEIGHT DIAGNOSIS / TREATMENT 60S HR
60S 
SBP 60S DBP
60S 
TOF% 90S HR
90S 
SBP 90S DBP
90S 
TOF% 120S HR
120S 
SBP 120S DBP
120S 
TOF%
1 1 MR ELUMALAI 45 M 11956 75 LT PYELOLITHOTOMY 88 114 70 74 88 118 76 58 91 118 76 22
2 1 MRS PARVATHY 32 F 14002 50 LAP CHOLECYSTECTOMY 85 124 72 72 85 124 72 56 88 129 76 13
3 1 MRS RADHA 30 F 12408 50 PB CONTRACTURE RELEASE & SSG 94 126 70 75 93 128 72 49 93 128 72 26
4 1 MR VINAYAGAM 45 M 12945 80 TRANS HIATAL ESOPHAGECTOMY 76 106 69 78 78 108 72 49 78 108 72 20
5 1 MRS SAROJA 50 F 10152 60 SUBTOTAL GASTRECTOMY WITH GJ 70 132 92 85 71 132 92 61 72 134 94 42
6 1 MR MUJBUR RAHMAN 18 M 17731 45 TONSIL ENUCLEATION & CURRETAGE 102 124 80 64 102 124 80 52 104 128 82 21
7 1 MR ANTHONY 35 M 17315 47 TONSILLECTOMY 85 114 68 80 86 118 68 62 86 118 68 36
8 1 MR SATHISHKUMAR 20 M 16188 51 NASAL POLYP FESS 91 122 72 61 93 124 74 43 93 124 74 20
9 1 MR KOTTI 24 M 12252 51 BILATERAL GYNAECOMASTIA REPAIR 93 128 84 78 93 128 84 56 95 130 88 24
10 1 MR SOLAI 25 M 17146 49 LT MASTOIDECTOMY & MYRINGOPLASTY 82 123 70 75 85 126 74 43 85 126 74 19
11 1 MR KATHIRVEL 36 M 13564 58 RT PYELOLITHOTOMY 91 132 82 74 93 134 82 54 93 134 84 39
12 1 MRS KRISHNAVENI 43 F 16282 50 RT DACROCYSTORHINOSTOMY 76 116 64 76 76 116 64 58 78 118 66 36
13 1 MR MANICKAM 35 M 11006 67 ETHMOIDAL POLYP FESS 64 104 68 80 62 108 71 62 67 108 72 48
14 1 MR RAJA 50 M 11843 64 BIL HERNIOPLASTY & BIL EVERSION OF SAC 91 130 84 76 93 130 84 54 93 134 88 31
15 1 MRS KAMALA 44 F 14321 51 LAP CHOLECYSTECTOMY 89 120 70 72 91 124 74 41 91 124 74 19
16 2 MRS POORNIMA 41 F 10036 45 RT MOD RADICAL MASTECTOMY 70 112 68 0 0 0
17 2 MR RAMAN 42 M 19947 44 REC CA COLON LAPROTOMY & PROCEED 98 120 68 0 0 0
18 2 MR JAINUL ABDEEN 54 M 23303 56 LAP/OPEN CHOLECYSTECTOMY 76 114 78 42 76 114 78 0 0
19 2 MR VENKATESAN 28 M 22827 60 POST BURNS: FOREHEAD FLAP COVER 114 132 90 33 114 132 90 0 0
20 2 MRS MANIMEGALAI 50 F 11487 55 OPEN CHOLECYSTECTOMY 69 116 76 30 71 116 76 2 76 0
21 2 MRS SARASU 42 F 21276 45 LAP/OPEN CHOLECYSTECTOMY 93 124 74 41 93 124 74 0 0
22 2 MR CHANDRAMOHAN 15 M 19691 45 TONSILLECTOMY 118 130 86 35 118 130 86 0 0
23 2 MR KARTHIKEYAN 30 M 12634 53 BIL INGUINAL HERNIOPLASTY 74 130 80 40 74 130 80 19 75 132 82 10
24 2 MRS MOHANA 50 F 18171 50 LT MOD RADICAL MASTECTOMY 87 132 90 0 0 0
25 2 MR KUMAR 21 M 18148 44 LAP APPENDICECTOMY 91 118 70 0 0 0
26 2 MR RAJA 31 M 17413 55 LT GYNAECOMASTIA REPAIR 75 130 64 0 0 0
27 2 MRS SUJATHA 35 F 10342 51 SUBTOTAL THYROIDECTOMY 62 118 70 45 63 118 70 0 0
28 2 MS ALAMELU 17 F 10531 40 LAP APPENDICECTOMY 62 104 62 0 0 0
29 2 MRS FATHIMA 46 F 10642 55 LAP CHOLECYSTECTOMY 72 114 80 45 73 116 80 0 0
30 2 MR RAJENDRAN 39 M 10145 60 BIL INGUINAL HERNIOPLASTY 86 114 74 40 87 116 76 0 0
31 3 MS PRIYA 16 F 24554 40 OPEN APPENDICECTOMY 99 109 74 91 99 109 74 64 103 109 78 48
32 3 MRS RAJAMMAL 48 F 22104 45 RT MOD RADICAL MASTECTOMY 70 118 70 85 70 118 70 62 72 118 72 44
33 3 MRS SAROJA 36 F 24512 53 LAP CHOLECYSTECTOMY 92 120 68 80 92 120 69 68 95 120 69 59
34 3 MR KANNIAPPAN 43 M 22140 50 SUBTOTAL GASTRECTOMY WITH GJ 82 116 84 78 82 116 84 64 83 116 86 35
35 3 MR ABDULLAH 36 M 27135 55 PARIETAL WALL TUMOR EXCISION 64 110 72 85 64 110 72 61 67 110 74 44
36 3 MRS RAJI 42 F 22245 55 LT HEMITHYROIDECTOMY 75 114 70 79 75 114 70 61 79 114 73 47
37 3 ME VELU 41 M 22017 59 RT PYELOLITHOTOMY WITH PUJ STENTING 83 132 72 70 85 133 74 60 85 133 74 51
38 3 MRS SHARMILA 29 F 24054 58 OPEN CHOLECYSTECTOMY 101 130 76 89 104 130 76 64 104 130 78 30
39 3 MRS JAYA 50 F 29095 50 RT PYELOLITHOTOMY WITH PUJ STENTING 78 128 82 82 75 126 84 74 79 126 84 56
40 3 MRS JAYA 45 F 23314 49 CHOLECYSTECTOMY WITH CBD EXPL 87 126 72 88 89 128 78 69 89 128 78 58
41 3 MS SANDHYA 18 F 14897 38 TONSILLECTOMY 107 112 70 91 107 112 70 86 109 112 74 54
42 3 MS ROSY 23 F 24053 40 TONSILLECTOMY 95 120 64 82 95 120 64 75 98 120 66 56
43 3 MRS RUKMANI 50 F 24426 55 LT MOD RADICAL MASTECTOMY 91 125 74 82 91 125 74 66 93 125 80 34
44 3 MRS VALARMATHI 34 F 22921 60 INCISIONAL HERNIA ANATOMICAL REPAIR 75 112 68 85 75 112 68 60 78 112 71 44
45 3 MR RAJENDRAN 38 M 24251 62 BIL HERNIOPLASTY & RT EVERSION OF SAC 86 122 84 84 86 122 84 61 89 122 88 48
